Merck KGaA Buys Serono, Gaining U.S. Commercial Organization
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.
You may also be interested in...
Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter
Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.